The standard therapies of surgery, radiotherapy, and hormonal manipulations often fail to control @entity263 (PC). @entity1205 and @entity2816 may have activity in refractory PC. We highlight the potential @entity358 when @entity1205 is combined with @entity2816 . We reviewed three examples of @entity1205 and @entity2816 @entity358 at the National @entity5 Institute (NCI) and summarized the published literature regarding @entity1205 and @entity2816 @entity358 . @entity1205 and @entity2816 @entity358 has the following four main presentations: (1). symptomatic effusions; (2). @entity1353 on exertion without any objective pathologic evidence; (3). @entity401 ; and (4). @entity358 . As chemotherapy becomes more common in the treatment of PC, clinicians must consider possible pulmonary @entity137 . If @entity358 or signs develop, clinicians should consider holding chemotherapy pending a complete evaluation.

@entity263 treatment with XXXX and @entity2816 .

@entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['metastatic prostate cancer'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity', 'pulmonary symptoms', 'pulmonary embolus'] @entity401 :: ('MESH:D017563', 'Disease') :: ['interstitial lung disease'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
